Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of 25 animals, also cause a spectrum of opportunistic infections including skin and soft tissue 26 infections, urinary tract infections, pneumonia, and bacteremia. However, recent 27 45 robustly inhibit DXR in zoonotic staphylococci, and further, DXR represents a 46 promising, druggable target for future development. 3 47 48 Author Summary 49 The proliferation of microbial pathogens resistant to the current pool of antibiotics is a 50 major threat to public health. Drug resistance is pervasive in staphylococci, including 51 several species that can cause serious zoonotic infections in humans. Thus, new 52 antimicrobial agents are urgently need to combat these life-threatening, resistant 53 infections. Here we establish the MEP pathway as a promising new target against 54 zoonotic staphylococci. We determine that fosmidomycin (FSM) selectively targets the 55 isoprenoid biosynthesis pathway in zoonotic staphylococci, and use forward genetics to 56 identify the transporter that facilitates phosphonate antibiotic uptake. Employing this 57 knowledge, we synthesized a series of potent antibacterial prodrugs that circumvent 58 the transporter. Together, these novel prodrug inhibitors represent promising leads for 59 further drug development against zoonotic staphylococci. 60 61 65 zoonotic infections in humans that are clinically indistinguishable from infections with S. 66 aureus including pneumonia, skin and soft tissue infections, hardware infections, and 67 bacteremia(1-5). Newer clinical microbiological techniques, such as mass 68 spectrometry, now readily distinguish S. aureus from zoonotic coagulase-positive
advances in bacterial identification have revealed that these common veterinary 28 pathogens are in fact, zoonoses that cause serious infections in human patients. The 29 global spread of multidrug-resistant zoonotic staphylococci, in particular the emergence 30 of methicillin-resistant organisms, is now a serious threat to both animal and human 31 welfare. Accordingly, new therapeutic targets that can be exploited to combat 32 staphylococcal infections are urgently needed. Enzymes of the methylerythritol 33 phosphate pathway (MEP) of isoprenoid biosynthesis represent potential targets for 34 treating zoonotic staphylococci. Here we demonstrate that fosmidomycin (FSM) inhibits 35 the first step of the isoprenoid biosynthetic pathway catalyzed by deoxyxylulose 36 phosphate reductoisomerase (DXR) in staphylococci. In addition, we have both 37 enzymatically and structurally determined the mechanism by which FSM elicits its 38 effect. Using a forward genetic screen, the glycerol-3-phosphate transporter GlpT that 39 facilitates FSM uptake was identified in two zoonotic staphylococci, Staphylococcus 40 schleiferi and Staphylococcus pseudintermedius. A series of lipophilic ester prodrugs 41 (termed MEPicides) structurally related to FSM were synthesized, and data indicate 42 that the presence of the prodrug moiety not only substantially increased potency of the 43 inhibitors against staphylococci, but also bypassed the need for GlpT-mediated cellular 44 transport. Collectively, our data indicate that the prodrug MEPicides selectively and Introduction 62 Coagulase-positive staphylococci, such as S. pseudintermedius and S. schleiferi 63 subsp. coagulans, are leading causes of skin, soft tissue, and invasive infections in 64 companion animals such as dogs and cats. In addition, these organisms cause 4 69 staphylococci, which were previously often misidentified(3,6,7). Thus, there is a 70 growing recognition of the importance of zoonotic staphylococci in human disease. 71 Because mecA-mediated methicillin resistance is on the rise in both veterinary and 72 human clinical isolates, new antibacterial strategies to specifically target zoonotic 73 staphylococci are highly desirable(8-10). 74 75 Two distinct and independent pathways for isoprenoid biosynthesis have evolved, the 76 mevalonate pathway and a mevalonate-independent route that proceeds through 77 methylerythritol phosphate, called the MEP pathway(11). Unusual among bacteria, the 78 least common ancestor of all Staphylococcus spp. appears to have possessed both 79 pathways. Primate-associated staphylococcal lineages, including S. aureus, possess 80 the mevalonate pathway, and evidence suggests that mevalonate pathway activity is 81 required for peptidoglycan synthesis, growth, and virulence (12) (13) (14) . In contrast, 82 nonprimate-associated staphylococcal species, including S. pseudintermedius and S. 83 schleiferi, utilize the MEP pathway for isoprenoid biosynthesis(15). Importantly, 84 humans and other mammals lack homologs of MEP pathway enzymes, and MEP 85 pathway activity is required for cellular growth in all organisms in which it has been 86 experimentally determined (16) (17) (18) (19) (20) (21) DXR(22) . FSM is safe and well-tolerated in humans and animals(23-25). 95 Unfortunately, FSM has poor oral bioavailability and a short serum half-life, which has 96 hampered clinical efficacy. Moreover, the charged nature of FSM and its phosphonate 97 analogs has challenged their clinical development as the compounds are excluded 98 from cells unless actively transported. As a result, many microorganisms, such as 99 Mycobacterium tuberculosis and Toxoplasma gondii, are inherently resistant to FSM 100 (due to poor cellular uptake) even though FSM potently inhibits their DXR orthologs in 101 vitro (16, 18, 26) . In Gram-negative organisms, FSM import is dependent on a glycerol-3-102 phosphate/Pi antiporter (GlpT), and FSM resistance can be achieved by reduced 103 expression or activity of GlpT(27, 28) . 104 
105
In this work, we use the highly specific inhibitor FSM to chemically validate the MEP 106 pathway enzyme DXR as an essential, druggable antibacterial target for zoonotic 107 staphylococcal infections. Furthermore, we establish the structural and enzymatic 108 mechanism of staphylococcal DXR inhibition by FSM. Using a chemical genomics 109 approach, we define the genetic basis of FSM resistance in zoonotic staphylococci and 110 define the FSM transporter GlpT in these strains. Finally, we reveal that structurally 111 related lipophilic ester prodrugs (called MEPicides) yield substantially increased 112 potency and circumvent the need for GlpT-dependent import. Thus, lipophilic prodrugs 113 provide a promising new approach to combat zoonotic staphylococcal infections. 
Results

116
Anti-staphylococcal activity of canonical MEP pathway inhibitors. 117 Because previous evidence had suggested that zoonotic staphylococci might be 118 sensitive to MEP pathway inhibition, we quantified the dose-dependent antibacterial 119 effects of FSM and FR-900098, a structurally similar DXR inhibitor ( Fosmidomycin is a competitive inhibitor of S. schleiferi DXR. 151 To establish the enzymatic mechanism-of-action of DXR inhibitors against 152 staphylococci, we cloned and purified S. schleiferi DXR ( Fig S2; Structural basis of fosmidomycin inhibition. 160 To establish the structural basis of FSM action, we solved the three-dimensional 161 structures of S. schleiferi DXR as an apoenzyme and a FSM complex to 2.15 Å and 162 2.89 Å resolution, respectively (Table S2 ; Fig 3) . S. schleiferi DXR is a physiologic 163 dimer with each monomer related by crystallographic symmetry ( Fig 3A) . A DALI Table S3 ). Fosmidomycin-resistance alleles of the candidate transporter, GlpT. 205 We predicted that the FSM-resistance alleles likely reduce GlpT function. In S. 206 schleiferi, nine distinct alleles were found with GlpT changes: two with nonsense 207 mutations and seven others with amino acid variants that are predicted to be highly 208 deleterious (Polyphen-2 score >0.9; Fig 6) .
234
Lipophilic prodrugs bypass need for GlpT-mediated transport. 235 We anticipated that our lipophilic ester prodrugs do not require active cellular transport. 236 To evaluate whether GlpT is required for prodrug uptake, we characterized the 12 237
MEPicide sensitivity of four different FSM R glpT mutant S. schleiferi strains. As 238 expected, we find that FSM R glpT strains are cross-resistant to the phosphonate parent 239 drug (compound 3), suggesting a common mechanism of transport ( Fig 5) . In contrast, 240 FSM R glpT strains remain sensitive to the MEPicide prodrugs compounds 2 and 4, 241 supporting a model in which GlpT mediates phosphonate transport, with the ester 242 modifications substantially improving cellular uptake ( Fig 6) our lipophilic prodrug compound 2 does not inhibit growth of these organisms (Table   272   S5 ). Our MEPicide compounds therefore have a highly specific and valuable 273 antimicrobial spectrum, which may help break the cycle of resistance transfer from 274 antibiotic-treated animals to the microbiota of humans.
275 276
In the current study, we establish the cellular, enzymatic, and structural mechanisms- glpT mutant strains indicates that the molecular basis of phosphonate resistance is 295 through loss of GlpT-mediated transport (Fig 6) . The prodrug MEPicides circumvent 296 GlpT, which our study has shown is easily mutated in staphylococci. Whether 297 staphylococci also readily develop resistance to the prodrug MEPicides is currently 298 unclear, and is an important question for future studies. It is important to note that while data indicate that the glpT mutants are resistant to 301 phosphonate parent compound 3, the magnitude of resistance is substantially less than 302 that of FSM. These data suggest that compound 3 may preferentially use an alternative 303 transporter, thereby bypassing the dependence on GlpT. Surprisingly, staphylococcal 304 glpT mutants are hypersensitive to MEPicide prodrugs, suggesting that after 15 305 penetration and cleavage by cellular esterases, the compounds may accumulate 306 intracellularly in the absence of GlpT ( Fig 5) . Future studies should examine the 307 cellular transport of the MEPicide compounds, and further, explore whether synergy 308 exists between the parent and prodrug varieties of this class of inhibitors. 
